Research graph
References from Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry
10.1016/j.clml.2019.10.009 · 2020 · External reference
Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US
10.1093/oncolo/oyad324 · 2024 · External reference
Diagnosis and treatment of chronic lymphocytic leukemia: a review
10.1001/jama.2023.1946 · 2023 · External reference
Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy
10.1002/ajh.27546 · 2025 · External reference
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
10.1016/s1470-2045(17)30909-9 · 2018 · External reference
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
10.1016/s1470-2045(24)00070-6 · 2024 · External reference
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
10.1111/bjh.15802 · 2019 · External reference
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
10.1038/s41408-022-00721-6 · 2022 · External reference
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
10.1182/bloodadvances.2023011327 · 2024 · External reference
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
10.3324/haematol.2018.193615 · 2018 · External reference
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group
10.1007/s00277-023-05304-4 · 2023 · External reference
Treatment effectiveness of venetoclax-based therapy after Bruton Tyrosine kinase inhibitors in chronic lymphocytic leukemia: an international real-world study
10.1002/ajh.27563 · 2025 · External reference
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
10.1080/10428194.2024.2310144 · 2024 · External reference
Venetoclax-rituximab and emerging treatment strategies after c-BTKi exposure in relapsed/refractory CLL: a real-world cohort and literature overview
10.3390/cancers17193159 · 2025 · External reference
Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: results from a multi-center international study
10.1016/j.clml.2023.03.010 · 2023 · External reference
Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (measurable) residual disease (MRD)
10.1182/blood-2021-145046 · 2021 · External reference
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment
10.1080/14796694.2024.2348440 · 2024 · External reference
